Resultados globales: 8 registros encontrados en 0.02 segundos.
Artículos, Encontrados 8 registros
Artículos Encontrados 8 registros  
1.
12 p, 608.0 KB Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk / Gatell, José Mª (Hospital Clínic i Provincial de Barcelona) ; Assoumou, Lambert (UPMC Univ Paris 06) ; Moyle, Graeme (St Chelsea and Westminster Hospital) ; Waters, Laura (Mortimer Market Center) ; Johnson, Margaret (Royal Free Hospital) ; Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ; Fox, Julie (Guys and St. Thomas Hospital) ; Martinez, Esteban (Hospital Clínic i Provincial de Barcelona) ; Stellbrink, Hans-Jürgen (ICH Study Centrum) ; Guaraldi, Giovanni (University of Modena and Reggio Emilia) ; Masia, Mar (Hospital General Universitario de Elche) ; Gompels, Marl (Southmead Hospital) ; De Wit, Stephane (Université Libre de Bruxelles) ; Florence, Eric (Institute of Tropical Medicine) ; Esser, Stefan (Universitatsklinikum) ; Raffi, François (CHU de Nantes) ; Pozniak, Anton L. (St Chelsea and Westminster Hospital) ; Universitat Autònoma de Barcelona
To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA less than 50 copies per ml for at least 24 weeks while on a PI/r regimen. [...]
2017 - 10.1097/QAD.0000000000001675
AIDS, Vol. 31 Núm. 18 (28 2017) , p. 2503-2514  
2.
11 p, 844.7 KB Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals / Kawana-Tachikawa, Ai (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Llibre, Josep M. (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Bravo, Isabel (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Escrig, Roser (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Mothe, Beatriz (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Puig, Jordi (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Puertas, Maria C. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Martinez-Picado, Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Blanco, Julià (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Manzardo, Christian (Hospital Clínic i Provincial de Barcelona) ; Miro, Jose M. (Hospital Clínic i Provincial de Barcelona) ; Iwamoto, Aikichi (The Institute of Medical Science, The University of Tokyo, Japan) ; Pozniak, Anton L. (HIV/GUM Department, Chelsea and Westminster Hospital, London, United Kingdom) ; Gatell, Jose M. (Hospital Clínic i Provincial de Barcelona) ; Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Brander, Christian (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ; Universitat Autònoma de Barcelona. Departament de Medicina
The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. [...]
2014 - 10.1371/journal.pone.0087334
PloS one, Vol. 9 (january 2014)  
3.
19 p, 1.1 MB Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort / Garriga, César (Instituto de Salud Carlos III) ; García de Olalla, Patricia (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ; Miró, Josep M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Ocaña Rivera, Immaculada (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya)) ; Barberà, Maria Jesús (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Humet, Victoria (Generalitat de Catalunya. Direcció General de Serveis Penitenciaris i de Rehabilitació) ; Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ; Gatell, Josep M.. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Ribera, Esteve (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Gurguí, Mercè (Institut d'Investigació Biomèdica Sant Pau) ; Marco, Andrés (Generalitat de Catalunya. Direcció General de Serveis Penitenciaris i de Rehabilitació) ; Caylà, Joan A.. (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)
Antiretroviral therapy has led to a decrease in HIV-related mortality and to the emergence of non-AIDS defining diseases as competing causes of death. This study estimates the HIV mortality rate and their risk factors with regard to different causes in a large city from January 2001 to June 2013. [...]
2015 - 10.1371/journal.pone.0145701
PloS one, Vol. 10 (december 2015)  
4.
13 p, 274.5 KB HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels / López-Dupla, Miguel (Hospital Universitari Joan XXIII de Tarragona) ; Maymó-Masip, Elsa (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ; Martínez, Esteban (Hospital Clínic i Provincial de Barcelona) ; Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ; Leal, Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Peraire, Joaquim (Hospital Universitari Joan XXIII de Tarragona) ; Viladés, Consuelo (Hospital Universitari Joan XXIII de Tarragona) ; Veloso, Sergi (Hospital Universitari Joan XXIII de Tarragona) ; Arnedo, Mireia (Hospital Clínic i Provincial de Barcelona) ; Ferrando-Martínez, Sara (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Beltrán-Debón, Raúl (Hospital Universitari Joan XXIII de Tarragona. Institut d'Investigació Sanitària Pere Virgili) ; Alba, Verónica (Hospital Universitari Joan XXIII de Tarragona. Institut d'Investigació Sanitària Pere Virgili) ; Gatell, Josep Mª (Hospital Clínic i Provincial de Barcelona) ; Vendrell, Joan (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ; Vidal, Francesc (Hospital Universitari Joan XXIII de Tarragona) ; Chacón, Matilde R. (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ; Universitat Autònoma de Barcelona
Obesity and HIV-1/HAART-associated lipodystrophy syndrome (HALS) share clinical, pathological and mechanistic features. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a multifunctional cytokine that plays an important role in obesity and related diseases. [...]
2015 - 10.1371/journal.pone.0144789
PloS one, Vol. 10 (december 2015)  
5.
14 p, 1.0 MB Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration : Randomized crossover clinical trial in healthy volunteers / Barroso, Sergio (Universitat Autònoma de Barcelona) ; Morén, Constanza (Universitat de Barcelona) ; González-Segura, Àlex (Universitat de Barcelona) ; Riba, Neus (Hospital Clínic i Provincial de Barcelona) ; Arnaiz, Joan A. (Hospital Clínic i Provincial de Barcelona) ; Manriquez, Marcela (Hospital Clínic i Provincial de Barcelona) ; Santana, Gemina (Hospital Clínic i Provincial de Barcelona) ; Blanco, José L. (Hospital Clínic i Provincial de Barcelona) ; Larousse, María (Hospital Clínic i Provincial de Barcelona) ; Loncà, Montse (Hospital Clínic i Provincial de Barcelona) ; de Lazzari, Elisa (Universitat de Barcelona) ; Llopis, Jaume (Universitat de Barcelona) ; Mallolas, Josep (Hospital Clínic i Provincial de Barcelona) ; Miró, Oscar (Hospital Clínic i Provincial de Barcelona) ; Carné, Xavier (Hospital Clínic i Provincial de Barcelona) ; Gatell, José M. (Hospital Clínic i Provincial de Barcelona) ; Garrabou, Glòria (Universitat de Barcelona) ; Martínez, Esteban (Hospital Clínic i Provincial de Barcelona)
Context Classical antiretroviral agents may acutely impact on metabolic, mitochondrial, renal and hepatic function in HIV-infected and uninfected persons. Fusion and integrase inhibitors are supposed to be safer, but have been scarcely investigated. [...]
2019 - 10.1371/journal.pone.0216712
PloS one, Vol. 14 Núm. 5 (may 2019) , p. e0216712  
6.
11 p, 1.6 MB Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 / Eron, J. J. (University of North Carolina School of Medicine) ; Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ; Cunningham, D. (Pueblo Family Physicians) ; Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Post, F. (King's College Hospital NHS Foundation Trust) ; De Wit, Stéphane (Université Libre de Bruxelles) ; Lathouwers, E. (Janssen Pharmaceutica NV) ; Hufkens, V. (Janssen Pharmaceutica NV) ; Jezorwski, J. (Janssen Research & Development) ; Petrovic, R. (Janssen Pharmaceutica NV) ; Brown, K. (Janssen Pharmaceutica NV) ; Van Landuyt, E. (Janssen Pharmaceutica NV) ; Opsomer, M. (Janssen Pharmaceutica NV) ; De Wit, Stéphane (Université Libre de Bruxelles) ; Florence, E. (Institute of Tropical Medicine) ; Moutschen, M. (Liège University Hospital (Bèlgica)) ; Van Wijngaerden, E. (University Hospitals Leuven (Bèlgica)) ; Vandekerckhove, L. (Ghent University Hospital. (Bèlgica)) ; Vandercam, B. (AIDS Reference center. Cliniques Universitaires Saint-Luc) ; Brunetta, J. (Maple Leaf Medical Clinic) ; Conway, B. (Vancouver Infectious Diseases Center) ; Klein, M. (Division of Infectious Diseases. Faculty of Medicine. McGill University Health Centre) ; Murphy, D. (Institut national de santé publique du Québec) ; Rachlis, A. (Sunnybrook Health Sciences Centre) ; Shafran, S. (Department of Medicine. University of Alberta) ; Walmsley, S. (University Health Network) ; Ajana, F. (Infectious Diseases Department. Tourcoing Hospital) ; Cotte, L. (Hospices Civils de Lyon. Hôpital de la Croix-Rousse) ; Girardy, P. M. (University Pierre & Marie Curie) ; Katlama, C. (HIV Clinical Research Unit) ; Molina, J. M. (Department of Infectious Diseases. St-Louis Hospital APHP. University of Paris Diderot) ; Poizot-Martin, I. (Clinical Immuno-Hematology Department. Aix-Marseille University. Sainte-Marguerite University Hospital and Inserm U912) ; Raffi, F. (CHU Hôtel Dieu) ; Rey, D. (Le Trait d'Union. HIV-Infection Care Center. Hôpitaux Universitaires de Strasbourg) ; Reynes, J. (University Hospital of Montpellier (França)) ; Teicher, E. (Infectious Diseases Department. APHP. Hôpital Bicêtre) ; Yazdanpanah, Y. ; Gasiorowski, J. (Independent Laboratory for Monitoring Infections among Drug Users at the Department of Infectious Diseases. Liver Disease and Acquired Immune Deficiencies. Wroclaw Medical University) ; Halota, W. (Department of Infectious Diseases and Hepatology. Nicolaus Copernicus University) ; Horban, A. (Medical University of Warsaw. Department for Adult's Infectious Diseases) ; Piekarska, A. (Department of Infectious Diseases and Hepatology. Medical University of Lodz) ; Witor, A. (Regional Hospital. Out-Patient's Clinic for Immune Deficiency) ; Arribas, J. R. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ; Perez-Valero, I. (Hospital Universitario La Paz (Madrid)) ; Berenguer, Juan (Hospital General Universitario Gregorio Marañón) ; Casado, José A. (Hospital Universitario Ramón y Cajal (Madrid)) ; Gatell, J. M. (Infectious Diseases Department. HCB) ; Gutiérrez, Félix (Hospital General Universitario de Elche) ; Galindo, María José (Hospital Clínic Universitari (València)) ; Gutiérrez Macià, Mª Del Mar (Institut d'Investigació Biomèdica Sant Pau) ; Iribarren, J. A. (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ; Knobel Freud, Hernando (Hospital del Mar (Barcelona, Catalunya)) ; Negredo Puigmal, Eugènia. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Pineda, J. A. (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; Podzamczer, Daniel (Institut d'Investigació Biomèdica de Bellvitge) ; Sogorb, J. P. (Hospital Universitario 12 de Octubre (Madrid)) ; Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Ricart, C. (Department of Microbiology. School of Medicine. University of Valencia) ; Rivero, Antonio (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Santos Gil, I. (Hospital Universitario de la Princesa (Madrid)) ; Blaxhult, A. (Department of Infectious Diseases. Venhälsan. Södersjukhuset) ; Flamholc, L. (Skåne University Hospital (Suècia)) ; Gisslèn, M. (Department of Infectious Diseases. University of Gothenburg) ; Thalme, A. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Fehr, J. (University Hospital Zurich (Suïssa)) ; Rauch, A. (Bern University Hospital) ; Stoeckle, M. (University Hospital Basel (Basilea, Suïssa)) ; Clarke, A. (Claude Nicol Centre. Royal Sussex County Hospital. Brighton and Sussex University Hospitals NHS Trust) ; Gazzard, B. G. (St. Stephen's Centre. Department of HIV/Genito-Urinary Medicine. Chelsea and Westminster Hospital) ; Johnson, M. A. (Queen Mary University) ; Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ; Post, F. (King's College Hospital NHS Foundation Trust) ; Ustianowski, Andrew (Regional Infectious Diseases Unit. North Manchester General Hospital) ; Waters, L. (University College London Hospital) ; Bailey, J. (Department of Medicine. Johns Hopkins University School of Medicine) ; Benson, P. (Be Well Medical) ; Bhatti, L. (AIDS Healthcare Foundation) ; Brar, I. (Henry Ford Hospital) ; Bredeek, U. F. (Metropolis Medical PC) ; Brinson, C. (Central Texas Clinical Research) ; Crofoot, G. (The Crofoot Research Center) ; Cunningham, D. (Pueblo Family Physicians) ; DeJesus, E. (Pueblo Family Physicians) ; Dietz, C. (Orlando Immunology Center) ; Dretler, R. (HIV Medicine. Kansas City Free Health Clinic) ; Eron, J. (Infectious Disease Specialists of Atlanta) ; Felizarta, F. (Private Practice) ; Fichtenbaum, C. (University of Cincinnati College of Medicine) ; Gallant, J. (Southwest CARE Center) ; Gathe, J. (Therapeutic Concepts) ; Hagins, D. (Georgia Department of Public Health. Chatham Care Center) ; Henn, S. (Whitman-Walker Health) ; Henry, W. K. (Department of Medicine. University of Minnesota Washington University School of Medicine) ; Huhn, G. (Ruth M. Rothstein CORE Center) ; Jain, M. (Department of Internal Medicine. University of Texas Southwestern Medical Center) ; Lucasti, C. (South Jersey Infectious Disease) ; Martorell, C. (Infectious Disease and The Research Institute) ; McDonald, C. (Tarrant County Infectious Disease Associates) ; Mills, A. (Southern California Men's Medical Group) ; Morales-Ramirez, J. (Clinical Research Puerto Rico Inc.) ; Mounzer, K. (Philadelphia FIGHT) ; Nahass, R. (ID Care) ; Olivet, H. (Community Research Initiative of New England) ; Osiyemi, O. (Triple O Research Institute PA) ; Prelutsky, D. (Department of Internal Medicine. Washington University School of Medicine) ; Ramgopal, M. (Midway Immunology Center. Fort Pierce) ; Rashbaum, B. (Capital Medical Associates) ; Richmond, G. (Broward General Medical Center) ; Ruane, P. (Ruane Clinical Research Group) ; Scarsella, A. (Pacific Oaks Medical Group) ; Scribner, A. (DCOL Center for Clinical Research) ; Shalit, P. (Peter Shalit MD and Associates) ; Shamblaw, D. (La Playa Medical Group) ; Slim, J. (Department of Infectious Diseases. Seton Hall University) ; Tashima, K. (The Miriam Hospital. Warren Alpert Medical School of Brown University) ; Voskuhl, G. (AIDS Arms. Inc.) ; Ward, D. (Dupont Circle Physicians Group) ; Wilkin, A. (Wake Forest School of Medicine) ; de Vente, J. (Living Hope Foundation) ; Universitat Autònoma de Barcelona
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. [...]
2019 - 10.1016/j.antiviral.2019.104543
Antiviral Research, Vol. 170 (october 2019) , p. 104543  
7.
10 p, 763.1 KB Engineering new mycobacterial vaccine design for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG / Saubi, Narcis (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Gea-Mallorquí, Ester (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Ferrer, Pau (Universitat Autònoma de Barcelona. Departament d'Enginyeria Química, Biològica i Ambiental) ; Hurtado, Carmen (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Sánchez-Úbeda, Sara (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Eto, Yoshiki (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Gatell, Josep M.. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Hanke, Tomáš (University of Oxford. Weatherall Institute of Molecular Medicine) ; Joseph, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
In this study, we have engineered a new mycobacterial vaccine design by using an antibiotic-free plasmid selection system. We assembled a novel Escherichia coli (E. coli)-mycobacterial shuttle plasmid p2auxo. [...]
2014 - 10.1038/mtm.2014.17
Molecular Therapy. Methods & Clinical Development, Vol. 1 (May 2014) , art. 14017  
8.
20 p, 1.4 MB A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART / Gómez, Carmen Elena (Centro Nacional de Biotecnología (Madrid, Espanya)) ; Perdiguero, Beatriz (Centro Nacional de Biotecnología (Madrid, Espanya)) ; García-Arriaza, Juan (Centro Nacional de Biotecnología (Madrid, Espanya)) ; Cepeda, Victoria (Centro Nacional de Biotecnología (Madrid, Espanya)) ; Sánchez-Sorzano, Carlos Óscar (Centro Nacional de Biotecnología (Madrid, Espanya)) ; Mothe, Beatriz (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Jiménez, José Luis (Hospital General Universitario Gregorio Marañón) ; Muñoz-Fernández, María Ángeles (Hospital General Universitario Gregorio Marañón) ; Gatell, José María (Hospital Clínic i Provincial de Barcelona) ; López Bernaldo de Quirós, Juan Carlos (Hospital General Universitario Gregorio Marañón) ; Brander, Christian (Institució Catalana de Recerca i Estudis Avançats) ; García, Felipe (Hospital Clínic i Provincial de Barcelona) ; Esteban, Mariano (Centro Nacional de Biotecnología (Madrid, Espanya)) ; Universitat Autònoma de Barcelona
TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. [...]
2015 - 10.1371/journal.pone.0141456
PloS one, Vol. 10 Núm. 11 (november 2015)  

Vea también: autores con nombres similares
1 Gatell, J.
1 Gatell, J. M.
1 Gatell, Jose
2 Gatell, Jose M.
2 Gatell, Josep M..
1 Gatell, Josep Mª
2 Gatell, José M.
1 Gatell, José María
1 Gatell, José Mª
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.